← Home
The All-In Podcast · May 1, 2026 · 1h 20m

OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze

Chamath Palihapitiya, Jason Calacanis, David Sacks, David Friedberg, David Friedberg, David Sacks, Jason Calacanis
Show Notes

The All-In crew discusses OpenAI's reported failure to meet internal targets amid the IPO race, Codex's competitive gains against Anthropic's Claude, the explosive growth of AI-driven cybersecurity, the trial pitting Elon Musk against Sam Altman, massive capex spending by hyperscalers, a cautionary tale of AI deleting a codebase, and the mainstream rise of peptide-based weight-loss drugs like retatrutide. Friedberg also recounts his experience at the Supreme Court.

This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.

Highlights

•
OpenAI Misses Internal Targets Ahead of IPO00:03:05
Chamath discusses reports that OpenAI failed to hit key revenue and user growth targets, raising doubts about the company’s IPO readiness.
ClaudeChatGPTGemini
•
Codex Surpasses Claude in Developer Benchmarks00:03:05
The group notes that OpenAI's Codex model is pulling ahead of Anthropic's Claude in coding tasks, suggesting the competitive landscape is shifting.
ClaudeChatGPTGemini
•
AI Cybersecurity: The Next Big Market00:20:02
The hosts explore how AI is creating a massive new cybersecurity market as attack surfaces and threats multiply.
ClaudeChatGPTGemini
•
The Elon vs. Sam Altman Trial Begins00:31:03
The crew breaks down the trial pitting Elon Musk against Sam Altman over control and mission alignment at OpenAI.
ClaudeChatGPTGemini
•
Hyperscaler Capex Explodes00:41:00
Big tech companies reported massive earnings beats alongside record capital expenditures, primarily driven by AI infrastructure buildouts.
ClaudeChatGPTGemini
•
Vibecoding Nightmare: AI Wipes a Codebase00:52:44
A story about a user whose entire codebase was deleted by a vibecoding AI tool illustrates the dangers of giving AI too much agency.
ClaudeChatGPTGemini
•
Retatrutide and the Peptide Craze00:58:33
The group examines the surging popularity of retatrutide and other peptides, which are moving from biohacking circles into mainstream weight management.
ClaudeChatGPTGemini

Editorial

•
Friedberg’s Supreme Court Experience01:06:34
Friedberg recounts his recent visit to the Supreme Court, sharing observations on the oral arguments and the atmosphere.
ClaudeChatGPTGemini
Was this useful?